SARS-CoV-2 reinfection rate before and after VOC Omicron emergence: a retrospective study in Brazil.

SARS-CoV-2 reinfection rate before and after VOC Omicron emergence: a retrospective study in Brazil.

Publication date: Jul 25, 2024

SARS-COV-2 reinfection has been reported worldwide, although its rate remains unclear. VOC Omicron’s emergence and its sub-variants led to an unprecedented number of COVID-19 cases in several countries, raising concerns regarding reinfection rates. 324,979 RT-qPCR-confirmed positive cases (72. 57% from Minas Gerais State) diagnosed between April 1, 2020, and August 31, 2022, at the Hermes Pardini, Grupo Fleury (Brazil) were used to estimate the reinfection rate. Instances of reinfection were characterized by two positive tests occurring with a minimum interval of 60 days. We identified 11,669 cases of reinfection. The states of Minas Gerais, ScE3o Paulo, Rio de Janeiro and GoicE1s represented almost 41% of the reinfections. Up until epidemiological week 46 of 2020, only 14 cases of reinfection were recorded. The majority of reinfections, totalling 6,316 cases, were detected during the circulation period of the Omicron and its sublineages BA. 1 and BA. 2. Another 4,273 reinfections occurred during the circulation period of sublineages BA. 4 and BA. 5, revealing two distinct groups of observations. The first group comprised cases of reinfection with a shorter time interval (two infections within a period of up to 200 days), while the second group was associated with a longer time interval (two infections within a period of more than 500 days). The reinfection rate during this period was nearly 8%, which is six times higher than the rate observed at the beginning of the study. In conclusion, our study underscores the dynamic nature of SARS-CoV-2 reinfections and their correlation with emerging variants such as Omicron.

Concepts Keywords
April Molecular diagnosis
August Real-world evidence
Brazil VOC Gamma
Infections VOC Omicron

Semantics

Type Source Name
disease MESH reinfection
disease MESH COVID-19
drug DRUGBANK Ribostamycin
disease VO time
disease MESH infections

Original Article

(Visited 1 times, 1 visits today)